A versatile H5N1-VSV platform for safe influenza virus research applications

Area of Science:

• Virology
• Immunology
• Vaccinology

Background:

• Highly pathogenic H5N1 influenza A virus (IAV) poses a significant threat to avian, mammalian, and human health, necessitating research under stringent Biosafety Level 3 (BSL-3) conditions.
• Vesicular stomatitis virus (VSV)-based vaccine vectors have demonstrated safety and efficacy in preclinical and clinical studies for various viral pathogens.
• Developing safe and adaptable research tools is crucial for understanding and combating emerging H5N1 IAV strains.

Discussion:

• A recombinant VSV expressing H5N1 IAV hemagglutinin (HA) and neuraminidase (NA) genes (H5N1-VSV) was developed as a versatile research platform.
• H5N1-VSV exhibited robust replication in cell lines, comparable to the wild-type H5N1 virus.
• The study identified antigenic site Sa polymorphisms in H5N1 strains from cattle under immune pressure, mirroring pandemic IAV evolution in humans.

Key Insights:

• H5N1-VSV vaccination in mice was safe, induced robust immunity, and conferred protection against a contemporary H5N1 strain.
• This VSV-based platform allows for studying H5N1 IAV biology without requiring BSL-3 containment for the full virus.
• The emergence of H5N1 polymorphisms highlights the importance of continuous surveillance and adaptable vaccine strategies.

Outlook:

• H5N1-VSV represents a promising, adaptable platform for influenza research and vaccine development.
• Further studies can explore the potential of H5N1-VSV in diverse animal models and for evaluating different vaccine formulations.
• This platform could accelerate the development of countermeasures against H5N1 and other emerging influenza viruses.